Issue 10, 2014

Graphene oxide modified with aptamer-conjugated gold nanoparticles and heparin: a potent targeted anticoagulant

Abstract

Graphene oxide (GO) modified with 29-mer thrombin-binding-aptamer-conjugated gold nanoparticles (TBA29–Au NPs/GO) can synergistically inhibit the thrombin-mediated cleavage of fibrinogen to fibrin. To further improve anticoagulation efficiency in human plasma, TBA29–Au NPs/heparin/GO has been prepared from TBA29–Au NPs/GO and heparin that can also bind thrombin. The dose-dependence of thrombin clotting time (TCT) delay caused by TBA29–Au NPs/heparin/GO is 21.4, 17.0 and >100 times higher than that caused by the TBA29–Au NPs, TBA29–Au NPs/GO and commercially available drugs (heparin, argatroban, hirudin or warfarin), respectively.

Graphical abstract: Graphene oxide modified with aptamer-conjugated gold nanoparticles and heparin: a potent targeted anticoagulant

Supplementary files

Article information

Article type
Communication
Submitted
03 May 2014
Accepted
11 Jul 2014
First published
23 Jul 2014

Biomater. Sci., 2014,2, 1332-1337

Author version available

Graphene oxide modified with aptamer-conjugated gold nanoparticles and heparin: a potent targeted anticoagulant

Y. So, H. Chang, W. Chiu and C. Huang, Biomater. Sci., 2014, 2, 1332 DOI: 10.1039/C4BM00156G

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements